Game-changing impact™

Driving transformation through game-changing innovation

Aneurysm Therapy

A brain aneurysm is a weak, bulging spot on the wall of an artery. Our unique portfolio for ruptured and unruptured aneurysms is backed by numerous clinical studies and independent research for great performance and versatility.

Ischemic Stroke and Carotid Artery Disease

A stroke is a permanent injury to the brain caused by a blockage of blood flow that deprives brain tissue of oxygen and nutrients. This diverse portfolio includes carotid stents, aspiration catheters, and mechanical thrombectomy products.

Neurovascular Malformations

Malformations are an abnormal tangle of blood vessels that cause arteries to shunt directly into veins, the blood flow never slows down enough to provide oxygen and nutrients. We took a novel approach by designing a ready-to-use liquid embolic device for malformations.

Access Product Solutions

Terumo Neuro develops a full range of access products, including catheters and guidewires, that allow physicians to gain access to the treatment area. We strive to provide a wide range of innovative, high-quality access products designed to improve patient outcomes.

Products

Our cutting-edge products lead the way in neuroendovascular therapies.

Latest Videos

Ischemic Stroke Patient Video

Tunisian Ischemic and Hemorrhagic Stroke Patient Stories

25th Anniverysary History of Innovations thumbnail

MicroVention's 25th Anniversary History of Innovations

Latest News

View newsroom

Sep 12, 2024

MicroVention Rebrands to Terumo Neuro - Reflects Expanded Focus and Strategic Growth

MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.

Jul 23, 2024

MicroVention Announces Release of CLinical EValuation of WEB™ 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms

MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced the recently published results of the CLinical EValuation of WEB 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms.

Jul 16, 2024

MicroVention Announces Settlement Against Former Employees for Trade Secret Misappropriation and Breach of Contract Among Other Claims

MicroVention announced today that the United States District Court for the Central District of California has issued an injunction permanently enjoining defendants David Ferrera, Nguyen (“Jake”) Le and Michelle Tran, former employees of MicroVention (“defendants”), from using, disclosing, or possessing any MicroVention trade secret information or confidential information.